Posts by Yin, Jiale

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights of this year’s conference were seven groundbreaking studies from Dr. Xiaowen Tang’s team at The First Affiliated Hospital of Soochow University. These included two oral presentations (O270, O683) and five poster presentations (P3384, P3493, P4197, P4284, P4836). Covering key areas such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), CAR-T cell therapy, and hematopoietic stem cell transplantation (HSCT), the research showcased the team's innovative contributions to hematology. Hematology Frontier interviewed Professor Tang on-site to explore the clinical significance of the two oral presentations, injecting new vitality into the advancement of hematology.

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest and most comprehensive international conference in hematology, successfully took place from December 7 to 10, 2024, in San Diego, USA. This annual event attracts numerous hematology experts and scholars worldwide to exchange ideas and discuss significant breakthroughs in the field. During this year's ASH conference, the Chinese American Hematologist and Oncologist Network (CAHON) held its 2024 Winter Symposium. Experts shared insights, reviewed past accomplishments, and presented cutting-edge advancements in areas ranging from basic research to clinical applications. The event not only fostered academic exchanges and knowledge sharing but also played a pivotal role in advancing the diagnosis and treatment of related diseases while promoting global professional collaboration.

The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, remains the largest and most comprehensive international academic gathering in the field of hematology. Every year, it draws leading experts and scholars from across the globe for in-depth discussions and exchanges on groundbreaking research. This year, the lymphoma field witnessed several pivotal study outcomes. Oncology Frontier - Hematology Frontier invited Dr. Jun Shi from The Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, to provide a detailed analysis and commentary on two highly impactful studies presented during the meeting.

Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with patient survival ranging from a few months to several decades. Therefore, after the diagnosis of CLL, it is particularly important to conduct an accurate and comprehensive prognostic assessment for patients. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7th to 10th, some research results on prognostic factors of CLL were announced. "Hematology Frontier" specially invited Dr. Shenmiao Yang from the Peking University Institute of Hematology, to select key studies from the conference and provide insightful commentary, aiming to offer valuable references and insights to colleagues in the field.

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As one of the largest and most prestigious international conferences in the field of hematology, ASH highlighted groundbreaking advancements and new drug development data, showcasing the highest levels of academic research globally. Platelet delay or engraftment failure is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Strategies to accelerate platelet engraftment remain a critical clinical challenge. At this year’s ASH meeting, Dr. Erlie Jiang and his team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) presented findings from their study (Abstract #266) investigating the effects of elevated recombinant human thrombopoietin (rhTPO) dosing on platelet engraftment in allo-HSCT. Hematology Frontier interviewed Prof. Jiang to explore the research findings and their implications.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this year’s conference, Dr. Yang Liang’s team from Sun Yat-sen University Cancer Center presented groundbreaking research on the mechanisms of clonal hematopoiesis (O192). The findings revealed a novel connection between DNMT3A mutations and immune microenvironment dysregulation, offering a fresh perspective on the origins and progression of clonal hematopoiesis. Hematology Frontier invited Dr. Liang for an in-depth discussion on the clinical significance of this research and its potential future applications.